Josh Kaplan is a medicinal chemist with extensive experience developing innovative therapeutic candidates. They invented pre-phase II candidate TLC-6740 and pre-phase I candidate TLC-1235, pioneering QD mitochondrial protonophores for metabolic disorders. Josh contributed significantly to the selection of GS-1291269, a neutral QD ketohexokinase inhibitor for kidney disease, and played a key role in the selection candidate GS-9901 for hematological and oncological indications. Currently, Josh consults in medicinal chemistry at BridGene Biosciences, having previously held positions at notable companies including Gilead Sciences, Pfizer, and Wyeth Ayerst Laboratories. They are pursuing an A.B. in Chemistry from Amherst College.
This person is not in the org chart
This person is not in any teams
This person is not in any offices